Current status and future perspectives of platelet-derived extracellular vesicles in cancer diagnosis and treatment
T Zhuang, S Wang, X Yu, X He, H Guo, C Ou - Biomarker Research, 2024 - Springer
Platelets are a significant component of the cell population in the tumour microenvironment
(TME). Platelets influence other immune cells and perform cross-talk with tumour cells …
(TME). Platelets influence other immune cells and perform cross-talk with tumour cells …
Omics Overview of the SPARC Gene in Mesothelioma
L Wu, M de Perrot - Biomolecules, 2023 - mdpi.com
The SPARC gene plays multiple roles in extracellular matrix synthesis and cell shaping,
associated with tumor cell migration, invasion, and metastasis. The SPARC gene is also …
associated with tumor cell migration, invasion, and metastasis. The SPARC gene is also …
SPARC is a novel positive immunohistochemical marker of epithelioid mesothelioma to differentiate it from lung adenocarcinoma and/or squamous cell carcinoma
T Nakagiri, VJ Amatya, K Kushitani… - The American Journal …, 2024 - journals.lww.com
Epithelioid mesothelioma with a solid histologic pattern (solid epithelioid mesothelioma) is
difficult to distinguish from a poorly differentiated squamous cell lung carcinoma and/or solid …
difficult to distinguish from a poorly differentiated squamous cell lung carcinoma and/or solid …
BAG2, MAD2L1, and MDK are cancer-driver genes and candidate targets for novel therapies in malignant pleural mesothelioma
L Bisceglia, F Morani, L Guerrieri… - Cancer Gene …, 2024 - nature.com
Malignant pleural mesothelioma (MPM) is an aggressive cancer with a poor prognosis and
the identification of novel druggable targets is urgently needed. In previous work, we …
the identification of novel druggable targets is urgently needed. In previous work, we …
Prognostic role of tumor immune microenvironment in pleural epithelioid mesothelioma
H Ollila, MI Mäyränpää, L Paavolainen… - Frontiers in …, 2022 - frontiersin.org
Background Pleural mesothelioma (MPM) is an aggressive malignancy with an average
patient survival of only 10 months. Interestingly, about 5%–10% of the patients survive …
patient survival of only 10 months. Interestingly, about 5%–10% of the patients survive …
Novel therapeutic approaches for pleural mesothelioma identified by functional ex vivo drug sensitivity testing
H Ollila-Raj, A Murumägi, T Pellinen, M Arjama… - Lung Cancer, 2023 - Elsevier
Objectives Pleural mesothelioma (PM) is an aggressive malignancy with limited treatment
options. The first-line therapy has remained unchanged for two decades and consists of …
options. The first-line therapy has remained unchanged for two decades and consists of …
A comprehensive study of alternative splicing in malignant pleural mesothelioma identifies potential therapeutic targets in a new cluster with poor survival
MM Shao, X Qiao, QY Chen, FS Yi - Thoracic Cancer, 2022 - Wiley Online Library
Background Malignant pleural mesothelioma (MPM) is one of the most aggressive tumors
with few effective treatments worldwide. It has been suggested that alternative splicing at the …
with few effective treatments worldwide. It has been suggested that alternative splicing at the …